ID | 48564 |
JaLCDOI | |
フルテキストURL | |
著者 |
Okada, Toshiaki
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Takigawa, Nagio
Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School
Kishino, Daizo
Department of Medicine, Yamaguchi-Ube Medical Center
Katayama, Hideki
Department of Medicine, Yamaguchi-Ube Medical Center
Kuyama, Shouichi
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Sato, Ken
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Mimoto, Junko
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Ueoka, Hiroshi
Department of Medicine, Yamaguchi-Ube Medical Center
Tanimoto, Mitsune
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Kaken ID
publons
researchmap
Kiura, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
抄録 | Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated
the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6).
|
キーワード | cisplatin
non-small cell lung cancer
celecoxib
cyclooxygenase-2
chemoprevention
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2012-06
|
巻 | 66巻
|
号 | 3号
|
出版者 | Okayama University Medical School
|
開始ページ | 245
|
終了ページ | 251
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2012 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |